Advertisement

Chemotherapy-induced peripheral neuropathy—patient-reported outcomes compared with NCI-CTCAE grade

  • Aaron C. Tan
  • J. Matt McCrary
  • Susanna B. Park
  • Terry Trinh
  • David GoldsteinEmail author
Original Article
  • 35 Downloads

Abstract

Background

Patient-reported outcomes (PRO) are becoming increasingly recognised as essential to comprehensively collect chemotherapy-induced peripheral neuropathy (CIPN) symptom information.

Materials and methods

This study aimed to evaluate the utility and feasibility of CIPN PRO assessment tools in a real-world clinical setting through investigation of the correlation of PRO with NCI-CTCAE assessments particularly in relation to cumulative dose of chemotherapy. Patients receiving oxaliplatin or paclitaxel chemotherapy in Sydney, Australia, completed a questionnaire containing standardised CIPN PRO assessments (EORTC CIPN-20, PRO-CTCAE) via tablet device. PRO assessment scores were correlated with NCI-CTCAE grade determined by nursing assessment and analysed with respect to cumulative dose of chemotherapy.

Results

There were 87 patients who completed a total of 145 questionnaires, 68 in patients receiving oxaliplatin and 77 in patients receiving paclitaxel. CIPN PRO scores were associated with NCI-CTCAE grade, for EORTC CIPN-20 (r2 = 0.19, p < 0.01) and PRO-CTCAE (r2 = 0.41, p < 0.01), although individual patient correlation was poor. PRO assessments, however, identified higher grade symptoms, in particular symptoms causing functional impairment, at lower doses of cumulative chemotherapy compared to NCI-CTCAE.

Conclusion

This study demonstrated that CIPN PRO may provide complementary information to nursing assessed NCI-CTCAE grade, particularly in earlier stages of chemotherapy and can be considered an important component in the comprehensive assessment of neuropathy.

Keywords

Chemotherapy-induced peripheral neuropathy CIPN Patient-reported outcomes PRO 

Notes

Funding information

This study was supported by a Cancer Institute NSW Program Grant (14/TPG/1-05) and a National Health and Medical Research Council of Australia (NHMRC) Project Grant (#1080521). SP is supported by a NHMRC Career Development Fellowship (#1148595).

Compliance with ethical standards

The study was approved by the South Eastern Sydney Local Health District (SESLHD) Human Research Ethics Committee (HREC) and patients provided informed signed consent.

Conflict of interest

The authors declare that they have no conflict of interest.

Disclosures

There are no relevant disclosures.

References

  1. 1.
    Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C (2008) Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 44:1507–1515.  https://doi.org/10.1016/j.ejca.2008.04.018 CrossRefGoogle Scholar
  2. 2.
    Tofthagen C (2010) Surviving chemotherapy for colon cancer and living with the consequences. J Palliat Med 13:1389–1391.  https://doi.org/10.1089/jpm.2010.0124 CrossRefGoogle Scholar
  3. 3.
    Park SB, Goldstein D, Krishnan AV, Lin CS, Friedlander ML, Cassidy J, Koltzenburg M, Kiernan MC (2013) Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin 63:419–437.  https://doi.org/10.3322/caac.21204 CrossRefGoogle Scholar
  4. 4.
    Mols F, Beijers T, Vreugdenhil G, van de Poll-Franse L (2014) Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. Support Care Cancer 22:2261–2269.  https://doi.org/10.1007/s00520-014-2255-7 CrossRefGoogle Scholar
  5. 5.
    McCrary JM, Goldstein D, Boyle F, Cox K, Grimison P, Kiernan MC, Krishnan AV, Lewis CR, Webber K, Baron-Hay S, Horvath L, Park SB (2017) Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey. Support Care Cancer 25:3485–3493.  https://doi.org/10.1007/s00520-017-3772-y CrossRefGoogle Scholar
  6. 6.
    Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176–181.  https://doi.org/10.1016/s1053-4296(03)00031-6 CrossRefGoogle Scholar
  7. 7.
    Cavaletti G, Frigeni B, Lanzani F, Mattavelli L, Susani E, Alberti P, Cortinovis D, Bidoli P (2010) Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer 46:479–494.  https://doi.org/10.1016/j.ejca.2009.12.008 CrossRefGoogle Scholar
  8. 8.
    Postma TJ, Heimans JJ, Muller MJ, Ossenkoppele GJ, Vermorken JB, Aaronson NK (1998) Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 9:739–744CrossRefGoogle Scholar
  9. 9.
    Alberti P, Rossi E, Cornblath DR, Merkies IS, Postma TJ, Frigeni B, Bruna J, Velasco R, Argyriou AA, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galie E, Briani C, Dalla Torre C, Faber CG, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey D, Kerrigan S, Schenone A, Fabbri S, Valsecchi MG, Cavaletti G (2014) Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. Ann Oncol 25:257–264.  https://doi.org/10.1093/annonc/mdt409 CrossRefGoogle Scholar
  10. 10.
    Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, Hoang-Xuan K, Lanteri-Minet M, Grant R, Huddart R, Moynihan C, Maher J, Lucey R (2005) The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 41:1135–1139.  https://doi.org/10.1016/j.ejca.2005.02.012 CrossRefGoogle Scholar
  11. 11.
    Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, Mendoza TR, Hay J, Atkinson TM, Abernethy AP, Bruner DW, Cleeland CS, Sloan JA, Chilukuri R, Baumgartner P, Denicoff A, St Germain D, O'Mara AM, Chen A, Kelaghan J, Bennett AV, Sit L, Rogak L, Barz A, Paul DB, Schrag D (2014) Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst 106:dju244.  https://doi.org/10.1093/jnci/dju244 CrossRefGoogle Scholar
  12. 12.
    Bennett AV, Dueck AC, Mitchell SA, Mendoza TR, Reeve BB, Atkinson TM, Castro KM, Denicoff A, Rogak LJ, Harness JK, Bearden JD, Bryant D, Siegel RD, Schrag D, Basch E (2016) Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Health Qual Life Outcomes 14:24.  https://doi.org/10.1186/s12955-016-0426-6 CrossRefGoogle Scholar
  13. 13.
    Knoerl R, Gray E, Stricker C, Mitchell SA, Kippe K, Smith G, Dudley WN, Lavoie Smith EM (2017) Electronic versus paper-pencil methods for assessing chemotherapy-induced peripheral neuropathy. Support Care Cancer 25:3437–3446.  https://doi.org/10.1007/s00520-017-3764-y CrossRefGoogle Scholar
  14. 14.
    Bennett AV, Jensen RE, Basch E (2012) Electronic patient-reported outcome systems in oncology clinical practice. CA Cancer J Clin 62:337–347.  https://doi.org/10.3322/caac.21150 CrossRefGoogle Scholar
  15. 15.
    Le-Rademacher J, Kanwar R, Seisler D, Pachman DR, Qin R, Abyzov A, Ruddy KJ, Banck MS, Lavoie Smith EM, Dorsey SG, Aaronson NK, Sloan J, Loprinzi CL, Beutler AS (2017) Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials. Support Care Cancer 25:3537–3544.  https://doi.org/10.1007/s00520-017-3780-y CrossRefGoogle Scholar
  16. 16.
    Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. biometrics 33:159–174CrossRefGoogle Scholar
  17. 17.
    Park SB, Kwok JB, Asher R, Lee CK, Beale P, Selle F, Friedlander M (2017) Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial. Ann Oncol 28:2733–2740.  https://doi.org/10.1093/annonc/mdx491 CrossRefGoogle Scholar
  18. 18.
    Di Maio M, Gallo C, Leighl NB, Piccirillo MC, Daniele G, Nuzzo F, Gridelli C, Gebbia V, Ciardiello F, De Placido S, Ceribelli A, Favaretto AG, de Matteis A, Feld R, Butts C, Bryce J, Signoriello S, Morabito A, Rocco G, Perrone F (2015) Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol 33:910–915.  https://doi.org/10.1200/jco.2014.57.9334 CrossRefGoogle Scholar
  19. 19.
    Inoue N, Ishida H, Sano M, Kishino T, Okada N, Kumamoto K, Ishibashi K (2012) Discrepancy between the NCI-CTCAE and DEB-NTC scales in the evaluation of oxaliplatin-related neurotoxicity in patients with metastatic colorectal cancer. Int J Clin Oncol 17:341–347.  https://doi.org/10.1007/s10147-011-0298-z CrossRefGoogle Scholar
  20. 20.
    Cirillo M, Venturini M, Ciccarelli L, Coati F, Bortolami O, Verlato G (2009) Clinician versus nurse symptom reporting using the National Cancer Institute—common terminology criteria for adverse events during chemotherapy: results of a comparison based on patient's self-reported questionnaire. Ann Oncol 20:1929–1935.  https://doi.org/10.1093/annonc/mdp287 CrossRefGoogle Scholar
  21. 21.
    Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, Appawu M, Iasonos A, Atkinson T, Goldfarb S, Culkin A, Kris MG, Schrag D (2009) Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst 101:1624–1632.  https://doi.org/10.1093/jnci/djp386 CrossRefGoogle Scholar
  22. 22.
    Atkinson TM, Li Y, Coffey CW, Sit L, Shaw M, Lavene D, Bennett AV, Fruscione M, Rogak L, Hay J (2012) Reliability of adverse symptom event reporting by clinicians. Qual Life Res 21:1159–1164CrossRefGoogle Scholar
  23. 23.
    Lavoie Smith EM, Barton DL, Qin R, Steen PD, Aaronson NK, Loprinzi CL (2013) Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 questionnaire. Qual Life Res 22:2787–2799.  https://doi.org/10.1007/s11136-013-0379-8 CrossRefGoogle Scholar
  24. 24.
    Ilson DH (2018) Adjuvant therapy in colon cancer: less is more. Lancet Oncol 19:442–443.  https://doi.org/10.1016/S1470-2045(18)30127-X CrossRefGoogle Scholar
  25. 25.
    Dueck AC, Mendoza TR, Mitchell SA, Reeve BB, Castro KM, Rogak LJ, Atkinson TM, Bennett AV, Denicoff AM, O'Mara AM, Li Y, Clauser SB, Bryant DM, Bearden JD 3rd, Gillis TA, Harness JK, Siegel RD, Paul DB, Cleeland CS, Schrag D, Sloan JA, Abernethy AP, Bruner DW, Minasian LM, Basch E (2015) Validity and reliability of the US National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). JAMA Oncol 1:1051–1059.  https://doi.org/10.1001/jamaoncol.2015.2639 CrossRefGoogle Scholar
  26. 26.
    Abernethy AP, Herndon JE 2nd, Wheeler JL, Patwardhan M, Shaw H, Lyerly HK, Weinfurt K (2008) Improving health care efficiency and quality using tablet personal computers to collect research-quality, patient-reported data. Health Serv Res 43:1975–1991.  https://doi.org/10.1111/j.1475-6773.2008.00887.x CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Medical OncologyRoyal North Shore HospitalSydneyAustralia
  2. 2.Prince of Wales Clinical SchoolUniversity of New South WalesSydneyAustralia
  3. 3.Brain and Mind CentreUniversity of SydneySydneyAustralia
  4. 4.Department of Medical Oncology, Nelune Cancer CentrePrince of Wales HospitalSydneyAustralia
  5. 5.Level 4, Lowy Cancer Research CentreUniversity of New South WalesSydneyAustralia

Personalised recommendations